Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01638546 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

97

Enrollment

NIH

Sponsor class

Conditions

Recurrent Lung Small Cell Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Placebo Administration
DRUG: Temozolomide
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)